ANNOUNCEMENT

NOBEL PRIZE 2026

This year's laureates, their fields, and the discoveries that earned them the prize.Live nowSee the winners
Moonbase
← Back to Awards
NIHNATIONAL CANCER INSTITUTER01

Metabolic Control and Anticancer Mechanism

Active
Institution
RUTGERS BIOMEDICAL AND HEALTH SCIENCES, NJ
Principal investigator
Steven Zheng
Funding
$295K
Duration
2021–2027
Open portfolio

Moonbase score

Still being scored

Abstract

ABSTRACT As a central controller of cancer growth and metabolism, mTORC1 pathway is commonly mutated and activated in human cancer, leading to uncontrolled growth. Cancer cells are ‘addicted’ to elevated mTORC1 signaling, rendering mTORC1 a desirable cancer drug target. The highly specific mTORC1 inhibitors rapamycin analogs (rapalogs, e.g. temsirolimus) are US FDA-approved oncology drugs. However, their clinical response has been moderate, which is in a large part due to incomplete understanding of mTORC1 signaling mechanisms underpinning rapamycin action. In this application, we will test the central hypothesis that nuclear mTORC1 signaling promotes aerobic glycolysis, or Warburg Effect, through a long non-coding RNA (lncRNA) NEAT1- dependent mechanism, which is important for mTORC1-driven tumorigenesis and rapamycin response. A successful completion of this project will provide a deeper understanding of this oncogenic pathway and therapeutic response to its blockage.

LOADING MOONBASE SCORE

R01NATIONAL CANCER INSTITUTEMechanisms of Cancer Therapeutics - 1 Study Section[MCT1]aerobic glycolysiscancer drugclinical responseblockagerapamycinnon-coding rnaspecific inhibitorslong non-coding

Questions for RUTGERS BIOMEDICAL AND HEALTH SCIENCES

Answered by the team behind this research.

No questions yet. Sign in to ask the first one

Related grants

Same researchers, same institution, same topic, scored first.